Clinical Trials Logo

Clinical Trial Summary

Along with the improvement of childhood acute leukemia treatment, survival rates have increased. Therefore, the number of long term childhood leukemia survivors has increased progressively over the last decades. So, the assessment of long term health status in this population becomes very important. Many studies have shown an increased risk of life threatening late complications and early mortality. Cardiovascular morbidity and mortality are particularly frequent. Among these late complications, the metabolic syndrome (MS) is an important concern since it is associated with cardiovascular morbidity and mortality. The overall MS prevalence in the French prospective cohort of survivors of childhood acute leukemia was 9.2% and 18.6% in cases of total body irradiation (TBI) during the leukemia treatment. Since the median age at MS evaluation was 21 years, this prevalence was very high. Anyway, the MS pathophysiology in this population is still poorly understood. One of the most recent hypothesis about the MS mechanism is based on the adipose tissue inability to store fatty acids: when adipose tissue cannot expanse further to store excess nutriments then lipids accumulate in other tissues. This ectopic lipids accumulation can cause insulin resistance and MS.

The investigators hypothesized that the adipose tissue could be damaged by treatments received during childhood acute leukemia treatment (particularly TBI). This leads to morphological and functional abnormalities that could promote the insulin resistance and MS.

This ectopic adipose tissue contains less preadipocytes, which could impair its functional properties.

The primary endpoint of this study is to compare the morphological and functional characteristics of adipose tissue in patients with a MS who received or not TBI during childhood leukemia treatment . This comparison will focus on:

- The adipose tissue repartition and evaluation of the ectopic adipose tissue

- Fibrosis and inflammation of the adipose tissue

- Preadipocytes quantification

The secondary endpoint is to describe:

- for the whole cohort of included patients,

- the clinical and biological characteristics associated with the MS.

- Cardiovascular risk factors and nutritional statement

- Anthropometric measurements

- Detection of other endocrinal abnormalities possibly associated with the MS

- Analysis of inflammation blood markers and adipokines quantification.


Clinical Trial Description

Enroled patients (both groups) will be evaluated for the following criteria. Then, a comparison between both groups will be performed.

1. Primary endpoint: the following factors will be studied, and compared between both groups (with or without TBI):

- Adipose tissue repartition using biphotonic absorptiometry and abdominal MRI

- Ectopic adipose tissue evaluation (visceral and hepatical) using MRI and proton spectroscopy

- Adipose tissue inflammation (using PCR array) : quantification of the following biomarkers: alpha TNF, IL6, IL1beta, IL10, MCP1, leptine and adiponectine

- Adipose tissue fibrosis (PCR array): quantification of the following markers of fibrosis: Col 1a1, Col 3a1, Col 6a1, Col 6a3, Tenascin C, Lumican, TGF beta

- Preadipocytes quantification in the adipose tissue (immunohistochemistery)

Concerning the secondary endpoints, the following points will be studied :

- Cardiovascular risk factors and nutritional statement

- Anthropometric measurements

- Other endocrinal abnormalities possibly associated with the MS

- Analysis of inflammation blood markers and adipokines quantification. ;


Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT02696304
Study type Interventional
Source Assistance Publique Hopitaux De Marseille
Contact Claire OUDIN, MD
Email claire.oudin@ap-hm.fr
Status Recruiting
Phase N/A
Start date May 2015
Completion date December 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02702375 - Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases N/A
Completed NCT02649348 - Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome N/A
Completed NCT02918422 - Controlled Clinical Study to Determine Novel Health Benefits of Cheese Consumption N/A
Completed NCT02459691 - Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos) N/A
Completed NCT02356952 - Effect of a Low Glycemic Index on Metabolic Syndrome N/A
Completed NCT02337933 - Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome Phase 2
Completed NCT02402985 - Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics N/A
Completed NCT01694056 - Soy Protein Intake and the Metabolic Syndrome N/A
Completed NCT00344903 - Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort N/A
Recruiting NCT00408824 - Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study) N/A
Completed NCT00362908 - Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome N/A
Completed NCT00395486 - ROMEO (Rosuvastatin in Metabolic syndrOme) Phase 4
Completed NCT00140816 - Dairy Products and Metabolic Effects (Norwegian Part) N/A
Completed NCT00101517 - Partnership Programs to Reduce Ethnic Differences in the Risk of Cardiovascular Disease N/A
Completed NCT00166036 - Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells Phase 2
Completed NCT00455325 - Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS) Phase 2
Recruiting NCT00177892 - Obstructive Sleep Apnea (OSA) and Metabolic Syndrome: Role of Oxidative Stress N/A
Completed NCT00074451 - Genomewide Search for Loci Underlying Metabolic Syndrome
Completed NCT00073775 - Epidemiology of Stress and the Metabolic Syndrome N/A
Completed NCT00200993 - Peripheral Effects of Exercise on Cardiovascular Health (STRRIDE I) Phase 2